Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Insmed reported Q1 2026 total revenue of $306.0 million, up 230% year-over-year, driven primarily by $207.9 million in sales from the newly launched BRINSUPRI. ARIKAYCE revenue grew 6% to $98.1 million, while the net loss narrowed to $0.76 per share from $1.42 a year ago. The company reaffirmed its 2026 full-year guidance, projecting at least $1 billion in BRINSUPRI revenue and $450 million to $470 million for ARIKAYCE.
Key figures
- Revenue
- $306.0 million
- Guidance
- 2026 BRINSUPRI revenue of at least $1 billion; 2026 ARIKAYCE revenue of $450 million to $470 million
- Revenue Yoy
- 230%
- Net loss
- $163.6 million
- Cash total
- $1.2 billion
- Rd expenses
- $209.5 million
- Sga expenses
- $247.3 million
- Arikayce revenue
- $98.1 million
- Brinsupri revenue
- $207.9 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.